SAB Biotherapeutics (SABS) has released an update to notify the public and investors about an entry into a material definitive agreement.
SAB Biotherapeutics, Inc. entered into a sales agreement with Cantor Fitzgerald & Co. to potentially sell up to $20 million of its common stock through at-the-market offerings. The sales are at the discretion of the company and will be conducted in compliance with the Securities Act and Nasdaq regulations. The proceeds are intended for pipeline development and general corporate purposes. The company agreed to pay the agent a 3% commission on sales, and either party can terminate the agreement with prior notice.
For further insights into SABS stock, check out TipRanks’ Stock Analysis page.
